A number of firms have modified their ratings and price targets on shares of SAGE Therapeutics (NASDAQ: SAGE) recently:

  • 8/9/2019 – SAGE Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/7/2019 – SAGE Therapeutics had its price target lowered by analysts at Oppenheimer Holdings Inc. from $200.00 to $190.00. They now have an “outperform” rating on the stock.
  • 7/27/2019 – SAGE Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/25/2019 – SAGE Therapeutics had its price target raised by analysts at Oppenheimer Holdings Inc. from $170.00 to $200.00.
  • 7/24/2019 – SAGE Therapeutics had its “buy” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 7/24/2019 – SAGE Therapeutics had its “buy” rating reaffirmed by analysts at William Blair.

Shares of NASDAQ:SAGE traded down $0.90 on Wednesday, hitting $164.68. 6,724 shares of the company’s stock were exchanged, compared to its average volume of 509,183. The stock’s 50-day moving average is $175.23. The stock has a market capitalization of $8.55 billion, a P/E ratio of -20.38 and a beta of 2.53. SAGE Therapeutics Inc has a 1-year low of $79.88 and a 1-year high of $193.56. The company has a debt-to-equity ratio of 0.03, a current ratio of 16.00 and a quick ratio of 16.00.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($3.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.32) by $0.04. The business had revenue of $0.87 million for the quarter, compared to analyst estimates of $0.27 million. The company’s revenue was down 99.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.36) earnings per share. Equities analysts predict that SAGE Therapeutics Inc will post -13.32 EPS for the current fiscal year.

In other news, insider Michael Cloonan sold 25,000 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $175.00, for a total transaction of $4,375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jeffrey M. Jonas sold 84,661 shares of the company’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $174.83, for a total value of $14,801,282.63. Following the transaction, the chief executive officer now directly owns 97,851 shares of the company’s stock, valued at $17,107,290.33. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 203,925 shares of company stock valued at $35,648,917. Insiders own 4.60% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Icon Wealth Partners LLC acquired a new stake in shares of SAGE Therapeutics in the 1st quarter valued at about $31,000. Mckinley Capital Management LLC Delaware boosted its position in shares of SAGE Therapeutics by 53.3% in the 1st quarter. Mckinley Capital Management LLC Delaware now owns 282 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 98 shares during the period. Cornerstone Advisors Inc. boosted its position in shares of SAGE Therapeutics by 28.3% in the 1st quarter. Cornerstone Advisors Inc. now owns 308 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 68 shares during the period. Quadrant Capital Group LLC boosted its position in shares of SAGE Therapeutics by 4,871.4% in the 1st quarter. Quadrant Capital Group LLC now owns 348 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 341 shares during the period. Finally, Manchester Capital Management LLC acquired a new stake in shares of SAGE Therapeutics in the 1st quarter valued at about $58,000.

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Further Reading: Diversification in Your Portfolio

Receive News & Ratings for SAGE Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.